Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR oncogenic variants status confers therapeutic sensitivity to Dacomitinib in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved dacomitinib for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
This statement is based on a regulatory approval from the Health Service Executive:
Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations